Can we help you?

You are here

What is the Difference Between Different Types of Dermal Fillers? What is Better Restylane® vs. Juvéderm®?

Error message

  • Notice: Undefined index: #attached in metatag_hreflang_metatag_metatags_view_alter() (line 72 of /web/sites/svetlanadanovich/www/sites/all/modules/metatag/metatag_hreflang/metatag_hreflang.module).
  • Notice: Undefined index: #attached in metatag_hreflang_metatag_metatags_view_alter() (line 79 of /web/sites/svetlanadanovich/www/sites/all/modules/metatag/metatag_hreflang/metatag_hreflang.module).
SD Professional Advice

The dermal fillers are becoming increasingly popular for rejuvenating the aging face. “According to the American Society for Aesthetic Plastic Surgery, Americans spent $12 billion on cosmetic procedures in 2014, with more than 10 million surgical and nonsurgical procedures performed. The top 5 nonsurgical procedures for both men and women combined were botulinum toxin, hyaluronic acid (HA), hair removal, chemical peel, and microdermabrasion.”

The variety of available dermal fillers is expanding, and it’s monumentally important to understand their specific characteristics in order to make the best choice for amazing results.

First, lets start with an overview of the dermal fillers that were approved by the US Food and Drug Administration over the last 10 years in order to understand the detailed indications for each of them to achieve the optimal results.

Restylane-L was the first product from the Restylane range to be approved for lip augmentation in 2012 by FDA. 

Restylane Silk (approved in 2014), which has been specifically designed for lip augmentation and correction of perioral rhytides.

Juvéderm Ultra and Juvéderm Ultra Plus, are FDA approved for the correction of moderate to severe facial wrinkles and folds.

Juvéderm Voluma XC was FDA approved in 2013 for deep injection for cheek augmentation.

But overall differences are the following:

Restylane was the first FDA-approved HA filler in 2003, and the first Juvéderm product was approved by the FDA in 2006. Juvéderm and Restylane are the bacterium-derived NASHA products. Juvéderm products have a much higher concentration of cross-linked HAs, which accounts for their longevity, and they are soft and easy to use. However, not ONLY the degree of cross -linking can affect the product’s longevity but also treatment areas and the patient’s metabolism. 

If you look at it carefully, you understand that no huge differences between 2 lines of product: Juvéderm vs. Restylane. You realize that there is no universal filler that can achieve ideal outcomes in all anatomic sites or in all patients. Often a combination approach may be ideal. Some patients may also benefit from a combination of both dermal fillers and neurotoxin injections, either on the same day or at separate visits, which may increase the longevity of the filler.